(NRC) National Research - Overview
Stock: Analytics, Insights, Patient, Employee, Experience
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.41% |
| Yield on Cost 5y | 1.14% |
| Yield CAGR 5y | 2.02% |
| Payout Consistency | 79.0% |
| Payout Ratio | 123.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 64.3% |
| Relative Tail Risk | -5.62% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.17 |
| Alpha | -15.52 |
| Character TTM | |
|---|---|
| Beta | 0.773 |
| Beta Downside | 0.361 |
| Drawdowns 3y | |
|---|---|
| Max DD | 77.58% |
| CAGR/Max DD | -0.35 |
Description: NRC National Research December 29, 2025
National Research Corp (NASDAQ:NRC) delivers subscription-based analytics that help health systems measure and improve patient and employee experiences across touch-points such as care transitions, service recovery, reputation management, and brand loyalty. Its platform aggregates real-time feedback, applies AI-driven “Huey” insights, and offers governance tools for board and physician leadership, positioning the firm as a comprehensive experience-management partner for U.S. providers.
Key operating metrics (FY 2023) show $210 million in revenue, a 9 % year-over-year increase driven primarily by higher adoption of its digital experience suite, and an ARR churn rate of roughly 5 %-a level considered strong for SaaS-focused health-tech firms. The business benefits from macro trends such as the shift toward value-based care, which ties reimbursement to patient satisfaction scores, and the broader acceleration of AI adoption in healthcare operations, both of which expand the addressable market for experience-management solutions.
For a deeper dive into how NRC’s data platform compares with peers, you might explore ValueRay’s analyst toolkit for additional quantitative benchmarks.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 11.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -2.80 > 1.0 |
| NWC/Revenue: -11.94% < 20% (prev -11.36%; Δ -0.58% < -1%) |
| CFO/TA 0.20 > 3% & CFO 26.4m > Net Income 11.6m |
| Net Debt (74.9m) to EBITDA (30.2m): 2.48 < 3 |
| Current Ratio: 0.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (21.8m) vs 12m ago -6.67% < -2% |
| Gross Margin: 56.33% > 18% (prev 0.60%; Δ 5573 % > 0.5%) |
| Asset Turnover: 102.8% > 50% (prev 107.9%; Δ -5.18% > 0%) |
| Interest Coverage Ratio: 4.75 > 6 (EBITDA TTM 30.2m / Interest Expense TTM 4.76m) |
Altman Z'' -0.23
| A: -0.12 (Total Current Assets 20.2m - Total Current Liabilities 36.6m) / Total Assets 134.9m |
| B: -0.13 (Retained Earnings -17.3m / Total Assets 134.9m) |
| C: 0.17 (EBIT TTM 22.6m / Avg Total Assets 133.7m) |
| D: -0.14 (Book Value of Equity -17.3m / Total Liabilities 120.9m) |
| Altman-Z'' Score: -0.23 = B |
Beneish M -3.08
| DSRI: 1.03 (Receivables 11.1m/11.2m, Revenue 137.4m/143.1m) |
| GMI: 1.07 (GM 56.33% / 60.20%) |
| AQI: 1.00 (AQ_t 0.55 / AQ_t-1 0.55) |
| SGI: 0.96 (Revenue 137.4m / 143.1m) |
| TATA: -0.11 (NI 11.6m - CFO 26.4m) / TA 134.9m) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
What is the price of NRC shares?
Over the past week, the price has changed by -21.63%, over one month by -17.41%, over three months by +12.11% and over the past year by -2.03%.
Is NRC a buy, sell or hold?
- StrongBuy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NRC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 15 | -6.1% |
NRC Fundamental Data Overview February 07, 2026
P/S = 2.6271
P/B = 24.7084
Revenue TTM = 137.4m USD
EBIT TTM = 22.6m USD
EBITDA TTM = 30.2m USD
Long Term Debt = 76.0m USD (from longTermDebt, two quarters ago)
Short Term Debt = 4.01m USD (from shortTermDebt, last quarter)
Debt = 79.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 74.9m USD (from netDebt column, last quarter)
Enterprise Value = 435.8m USD (360.9m + Debt 79.0m - CCE 4.14m)
Interest Coverage Ratio = 4.75 (Ebit TTM 22.6m / Interest Expense TTM 4.76m)
EV/FCF = 27.68x (Enterprise Value 435.8m / FCF TTM 15.7m)
FCF Yield = 3.61% (FCF TTM 15.7m / Enterprise Value 435.8m)
FCF Margin = 11.46% (FCF TTM 15.7m / Revenue TTM 137.4m)
Net Margin = 8.44% (Net Income TTM 11.6m / Revenue TTM 137.4m)
Gross Margin = 56.33% ((Revenue TTM 137.4m - Cost of Revenue TTM 60.0m) / Revenue TTM)
Gross Margin QoQ = 54.31% (prev 57.81%)
Tobins Q-Ratio = 3.23 (Enterprise Value 435.8m / Total Assets 134.9m)
Interest Expense / Debt = 1.73% (Interest Expense 1.37m / Debt 79.0m)
Taxrate = 45.01% (1.47m / 3.27m)
NOPAT = 12.4m (EBIT 22.6m * (1 - 45.01%))
Current Ratio = 0.55 (Total Current Assets 20.2m / Total Current Liabilities 36.6m)
Debt / Equity = 5.65 (Debt 79.0m / totalStockholderEquity, last quarter 14.0m)
Debt / EBITDA = 2.48 (Net Debt 74.9m / EBITDA 30.2m)
Debt / FCF = 4.76 (Net Debt 74.9m / FCF TTM 15.7m)
Total Stockholder Equity = 19.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.67% (Net Income 11.6m / Total Assets 134.9m)
RoE = 58.50% (Net Income TTM 11.6m / Total Stockholder Equity 19.8m)
RoCE = 23.58% (EBIT 22.6m / Capital Employed (Equity 19.8m + L.T.Debt 76.0m))
RoIC = 12.79% (NOPAT 12.4m / Invested Capital 97.2m)
WACC = 7.37% (E(360.9m)/V(440.0m) * Re(8.77%) + D(79.0m)/V(440.0m) * Rd(1.73%) * (1-Tc(0.45)))
Discount Rate = 8.77% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.75%
[DCF Debug] Terminal Value 77.56% ; FCFF base≈17.1m ; Y1≈14.1m ; Y5≈10.1m
Fair Price DCF = 6.02 (EV 211.1m - Net Debt 74.9m = Equity 136.3m / Shares 22.6m; r=7.37% [WACC]; 5y FCF grow -21.18% → 2.90% )
EPS Correlation: -73.66 | EPS CAGR: -45.98% | SUE: 0.0 | # QB: 0
Revenue Correlation: -78.52 | Revenue CAGR: -2.33% | SUE: N/A | # QB: 0